TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05837845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Participants will receive 12-16 sessions of Cognitive Processing Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MDMA-assisted Therapy
Description: Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.
Study: NCT05416983

Intervention type: PROCEDURE
Intervention: Discussion
Description: Attend discussion

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT06277960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous intramyocardial septal radiofrequency ablation system
Description: The device is introduced into the right ventricle and performs ablation treatment on the hypertrophic interventricular septum.
Study: NCT04999202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2416964
Description: The highest dose determined safe in combination with pembrolizumab in the dose escalation part or a lower dose. More than one dose may be explored in the dose expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks
Study: NCT06633965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIDANET
Description: AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIDANET
Description: AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
Study: NCT05408611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupressure
Description: Placebo acupressure is manual pressure applied to unreal acupressure points.
Study: NCT04950309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQUID MEG
Description: MEG recordings acquired on a standard whole brain SQUID MEG system. Stimuli will be used, including auditory, visual, or somatosensory stimuli. Language stimuli and median nerve stimulation may also be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPM MEG
Description: MEG recordings acquired on an investigational OPM MEG system. Stimuli will be used, including auditory, visual, or somatosensory stimuli. Language stimuli and median nerve stimulation may also be used.
Study: NCT06340347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367
Study: NCT06386003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.
Study: NCT05482789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 10 microgram injected sub-cutaneously once
Study: NCT05377021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle change
Description: In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle change
Description: In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention.
Study: NCT05759338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revian Red All LED cap
Description: The cap is a dual-band LED light therapy wireless smart cap. It has been shown to be effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women.
Study: NCT06307626

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous efgartigimod PH20 SC given by prefilled syringe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC
Description: Subcutaneous placebo given by prefilled syringe
Study: NCT05327946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 770371
Description: BI 770371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 770371
Description: BI 770371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezabenlimab
Description: ezabenlimab
Study: NCT06059144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous norepinephrine
Description: Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
Study: NCT05002205

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be followed up by means of online surveys and 2 study visits.

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be followed up by means of online surveys and 2 study visits.

Intervention type: OTHER
Intervention: spirometry
Description: During two study visits, the lung function will be measured (FVC, FEV1)
Study: NCT04187625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: endothelial progenitor cell
Description: Kidney-derived endothelial progenitor cells will be delivered percutaneously to the kidney blood supply.
Study: NCT05002205

Intervention type: OTHER
Intervention: spirometry
Description: During two study visits, the lung function will be measured (FVC, FEV1)

Intervention type: OTHER
Intervention: ECG
Description: During two study visits, the presence of arrhythmia will be explored.
Study: NCT05311839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Hot packs, active range of motion exercises, pendular exercises, wall climb exercises, mobilization exercises, and shoulder capsular stretching
Study: NCT05002205

Intervention type: OTHER
Intervention: ECG
Description: During two study visits, the presence of arrhythmia will be explored.

Intervention type: OTHER
Intervention: 1 minute sit to stand test
Description: Physical endurance is tested during 2 study visits.

Intervention type: OTHER
Intervention: 1 minute sit to stand test
Description: Physical endurance is tested during 2 study visits.

Intervention type: OTHER
Intervention: Vital parameters
Description: blood pressure, pulse, weight

Intervention type: OTHER
Intervention: Vital parameters
Description: blood pressure, pulse, weight
Study: NCT05311839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Hot packs, active range of motion exercises, pendular exercises, wall climb exercises, mobilization exercises, and shoulder capsular stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thera band
Description: graded Thera band exercises for shoulder flexion, abduction, internal, and external rotation
Study: NCT04744116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cellular Therapy
Description: Given ds-MSCs IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cellular Therapy
Description: Given ds-MSCs IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study: NCT04775238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silver nanoparticles
Description: AgNPs (19±5 nm)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silver nanoparticles
Description: AgNPs (19±5 nm)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Copper nanoparticles
Description: CuNPs (150-350 nm)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Copper nanoparticles
Description: CuNPs (150-350 nm)
Study: NCT06452654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty Injectable Product
Description: Vaccination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Vaccination
Study: NCT06175273

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Supplement
Description: 8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs. The formula will equate to 1.0kcal/mL

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tube Feed
Description: EN will have a feeding tube placed and started on tube feeds via a designated pump for overnight feeds, meeting at least 50% of estimated energy needs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: 0.25mg/kg/d divided BID. May titrate by 4mg increments to a max of 12mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 2.5mg once a day (at night). May titrate by 2.5mg increments to max of 10mg/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Diet education on high protein, high calorie food consumption
Study: NCT05661916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-TTRSC04
Description: ALN-TTRSC04 will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection.
Study: NCT05024968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Given by IV
Study: NCT06203184

Intervention type: OTHER
Group type: OTHER
Intervention: video based exercises
Description: Respiratory muscle training and other factors will be examined through 12 weeks of video-based game exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video based exercises
Description: Respiratory muscle training and other factors will be examined through 12 weeks of video-based game exercises.
Study: NCT05757869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milvexian
Description: Milvexian will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Apixaban will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Milvexian matching milvexian placebo will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban Placebo
Description: Apixaban matching apixaban placebo will be administered orally.
Study: NCT05498285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPSCALER app
Description: Usage of mobile app to guide rehabilitation after surgery
Study: NCT04850404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal nerve block
Description: All Patients of group A-M will be administered with rectus abdominis block combined with TAPB after anesthesia. Rocuronium was infused continuously (concentration: 1 mg/ml) when TOF recovered to 1. The starting rate was 0.3mg/kg/h, and the TOF count was maintained between 1\~3 (moderate NMB) and recorded during the operation. Whether and how to add rocuronium was based on TOF count and request of surgeons. When TOF Watch- SX showed 4 or ratio, the investigators increased the speed of rocuronium pump infusion and record the score at the time of shallow NMB. When the chief surgeon thought the vision could not satisfy the needs of the operation, rocuronium 0.1mg/kg in bolus was added as a rescue. Then, the pump speed was lowered or even decreased to 0 to make the TOF count recover to 1\~3 as soon as possible.
Study: NCT05925634

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RPE (usual care)
Description: Patients in the active comparator group will follow standard exercise prescription protocols in cardiac rehabilitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GXT+THHR (intervention)
Description: Patients in the personalized care group will perform a graded exercise test and the peak heart rate from the test will allow the researcher to calculate a target heart rate range (THRR). Then, the patients will receive psychoeducational feedback (PF) about their test results and exercise performance. After PF, their THRR will be reviewed and how it will be used to guide exercise intensity in CR will be discussed.
Study: NCT04704154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib, (Stivarga, BAY73-4506)
Description: Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off).~If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (Opdivo)
Description: 480 mg administered on Day 1 of each treatment cycle.
Study: NCT05999786

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: early rehabiliation swallowing program
Description: not receiving early rehabilitation swallowing program from before and after surgery

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: not receiving early rehabilitation swallowing program
Description: the Taiwan Dysphagia Society's publicly shared swallowing exercises for dysphagia, which is from before and after surgery
Study: NCT05322070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide Intravitreal Implant 0.18 mg
Description: YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
Study: NCT05616507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fucoidan
Description: It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
Study: NCT06480240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-992
Description: OBI-992 is an antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-992
Description: OBI-992 is an antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-992
Description: OBI-992 is an antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-992
Description: OBI-992 is an antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-992
Description: OBI-992 is an antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-992
Description: OBI-992 is an antibody-drug conjugate
Study: NCT05936528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: antioxidant, immunomodulatory, anti-inflammatory, antimicrobial, and antiviral effect
Study: NCT06331403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Group Intervention
Description: Weekly virtual group meetings with the study interventionist(s) and up to 9 other female cancer survivors over an approximately 6 week period. The group program includes topics related to coping with physical health changes, managing social factors relevant to sexual well-being, and managing thoughts and feelings related to sexual well-being changes.
Study: NCT04863989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tube thoracostomy
Description: insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tube thoracostomy
Description: insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax
Study: NCT05061537

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07263689
Description: Genetically engineered oncolytic vaccinia virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07263689
Description: Genetically engineered oncolytic vaccinia virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07263689
Description: Genetically engineered oncolytic vaccinia virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07263689
Description: Genetically engineered oncolytic vaccinia virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07263689
Description: Genetically engineered oncolytic vaccinia virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2
Study: NCT06480240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-992
Description: OBI-992 is an antibody-drug conjugate
Study: NCT06056921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 targeted CAR-T cells
Description: A single infusion of CD19 CAR-T cells will be administered intravenously
Study: NCT06087913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF/EVG vaginal insert
Description: vaginal insert applied daily for 3 days then every other day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo vaginal insert
Description: vaginal insert applied daily for 3 days then every other day for 14 days
Study: NCT05736965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor 60mg, PO d3,10,17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75mg/m2, IV d1-3, 8-9, 15-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 100mg PO on day 1 and 200mg on day 2, 400mg on day 3-14
Study: NCT06422403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Dosing Interval - A
Description: Nivolumab 360mg 6 weekly (up to 2 years) + XELOX Nivolumab 240mg 4 weekly (up to 2 years) + FOLFOX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Dosing Interval - B
Description: Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Dosing Interval - C
Description: Pembrolizumab 200mg 6 weekly (up to 2 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - A
Description: Nivolumab 360mg 3 weekly (up to 2 years) + XELOX Nivolumab 240mg 2 weekly (up to 2 years) + FOLFOX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - B
Description: Bevacizumab + Atezolizumab 1200mg 3 weekly (up to 2 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - C
Description: Pembrolizumab 200mg 3 weekly (up to 2 years)
Study: NCT05554159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Fitbit Program
Description: Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Exercise Program
Description: Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
Study: NCT06480240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-992
Description: OBI-992 is an antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-992
Description: OBI-992 is an antibody-drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-992
Description: OBI-992 is an antibody-drug conjugate
Study: NCT05266963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CREON
Description: The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo